Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 9/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19963222 | 0.91 | CYP1A2 (0.46) | MMECYP1A2ACETRPV1 | |
| SCHEMBL21986104 | 0.88 | MME (0.39) | MMECYP1A2SLC7A5ACETRPV1 | |
| SCHEMBL19963171 | 0.87 | NPC1 (0.38) | MMECYP1A2SLC7A5ACETRPV1 | |
| SCHEMBL21985995 | 0.87 | POLB (0.39) | MMECYP1A2SLC7A5ACETRPV1 | |
| SCHEMBL19963024 | 0.87 | ESR1 (0.42) | MMECYP1A2SLC7A5ACENPC1 | |
| SCHEMBL20544347 | 0.86 | PTGES (0.39) | CYP1A2 | |
| SCHEMBL29594552 | 0.86 | PTGES (0.39) | CYP1A2 | |
| SCHEMBL19963029 | 0.84 | PPARG (0.41) | MMEPOLB | |
| SCHEMBL20544661 | 0.83 | CRHBP (0.43) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL19963323 | 0.82 | KDM4E (0.40) | MMESLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108699013-B | Spiroquinone derivative, method for preparing the same, and pharmaceutical composition for preventing or treating neurological disorders containing the same as an active ingredient | 嘉泉大学校校产学协力团 | 2022-05-06 | — | — | CN | disclosed |
| US-10836734-B2 | Spiroquinone derivative compound, production method thereof, and pharamaceutical composition for preventing or treating neurological disorders which contains same as active ingredient | GACHON UNIVERSITY OF INDUSTRY—ACADEMIC COOPERATION FOUNDATION (KR) | 2020-11-17 | — | — | US | disclosed |
| US-10836734-B2 | Spiroquinone derivative compound, production method thereof, and pharamaceutical composition for preventing or treating neurological disorders which contains same as active ingredient | GACHON UNIVERSITY OF INDUSTRY—ACADEMIC COOPERATION FOUNDATION (KR) | 2020-11-17 | — | — | US | disclosed |
| EP-3395804-B1 | NOVEL SPIROQUINONE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS WHICH CONTAINS SAME AS ACTIVE INGREDIENT | UNIV GACHON IND ACAD COOP FOUND (KR) | 2020-05-13 | — | — | EP | disclosed |
| EP-3395804-B1 | NOVEL SPIROQUINONE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS WHICH CONTAINS SAME AS ACTIVE INGREDIENT | UNIV GACHON IND ACAD COOP FOUND (KR) | 2020-05-13 | — | — | EP | disclosed |
| US-20180327370-A1 | NOVEL SPIROQUINONE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREOF, AND PHARAMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS WHICH CONTAINS SAME AS ACTIVE INGREDIENT | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2018-11-15 | — | — | US | disclosed |
| EP-3395804-A1 | NOVEL SPIROQUINONE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS WHICH CONTAINS SAME AS ACTIVE INGREDIENT | Gachon University of Industry-Academic Cooperation Foundation (KR) | 2018-10-31 | — | — | EP | disclosed |
| WO-2018048261-A1 | NOVEL SPIROQUINONE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS WHICH CONTAINS SAME AS ACTIVE INGREDIENT | 가천대학교 산학협력단 | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836734-B2 | Spiroquinone derivative compound, production method thereof, and pharamaceutical composition for preventing or treating neurological disorders which contains same as active ingredient | NQO1, SDHA, SDHB | MME 2721/4885CYP1A2 347/4885SLC7A5 4343/4885 |
| US-20180327370-A1 | NOVEL SPIROQUINONE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREOF, AND PHARAMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS WHICH CONTAINS SAME AS ACTIVE INGREDIENT | NQO1, SDHA, KEAP1 | MME 2928/4885CYP1A2 683/4885SLC7A5 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.